Halbert Hargrove Global Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $269K | Buy |
1,070
+20
| +2% | +$4.3K | 0.01% | 93 |
|
|
2026
Q1 | $228K | Hold |
1,050
| – | – | 0.01% | 87 |
|
|
2025
Q4 | $240K | Sell |
1,050
-191
| -15% | -$43.5K | 0.01% | 84 |
|
|
2025
Q3 | $287K | Buy |
1,241
+1,191
| +2,382% | +$243K | 0.01% | 85 |
|
|
2025
Q2 | $9.28K | Sell |
50
-61
| -55% | -$11.3K | ﹤0.01% | 236 |
|
|
2025
Q1 | $23.2K | Sell |
111
-106
| -49% | -$20.6K | ﹤0.01% | 186 |
|
|
2024
Q4 | $38.6K | Buy |
+217
| New | +$39.9K | ﹤0.01% | 164 |
|
|
2023
Q2 | – | Sell |
-3,815
| Closed | -$608K | – | 95 |
|
|
2023
Q1 | $608K | Buy |
3,815
+444
| +13% | +$67.9K | 0.04% | 69 |
|
|
2022
Q4 | $545K | Buy |
3,371
+256
| +8% | +$39.3K | 0.04% | 75 |
|
|
2022
Q3 | $418K | Buy |
3,115
+132
| +4% | +$18.9K | 0.03% | 82 |
|
|
2022
Q2 | $457K | Sell |
2,983
-79
| -3% | -$12.1K | 0.03% | 76 |
|
|
2022
Q1 | $497K | Buy |
3,062
+163
| +6% | +$23.7K | 0.03% | 78 |
|
|
2021
Q4 | $393K | Buy |
2,899
+186
| +7% | +$22K | 0.03% | 94 |
|
|
2021
Q3 | $293K | Buy |
2,713
+19
| +0.7% | +$2.17K | 0.02% | 106 |
|
|
2021
Q2 | $303K | Sell |
2,694
-68
| -2% | -$7.66K | 0.02% | 110 |
|
|
2021
Q1 | $299K | Buy |
2,762
+282
| +11% | +$30.2K | 0.02% | 91 |
|
|
2020
Q4 | $266K | Sell |
2,480
-98
| -4% | -$9.42K | 0.02% | 88 |
|
|
2020
Q3 | $226K | Sell |
2,578
-623
| -19% | -$58.7K | 0.02% | 91 |
|
|
2020
Q2 | $314K | Buy |
3,201
+412
| +15% | +$36.3K | 0.05% | 60 |
|
|
2020
Q1 | $212K | Buy |
2,789
+125
| +5% | +$10.6K | 0.04% | 72 |
|
|
2019
Q4 | $236K | Sell |
2,664
-116
| -4% | -$9.63K | 0.06% | 70 |
|
|
2019
Q3 | $210K | Sell |
2,780
-80
| -3% | -$5.49K | 0.06% | 78 |
|
|
2019
Q2 | $208K | Buy |
2,860
+108
| +4% | +$8.49K | 0.06% | 75 |
|
|
2019
Q1 | $222K | Sell |
2,752
-310
| -10% | -$25.4K | 0.78% | 39 |
|
|
2018
Q4 | $282K | Buy |
3,062
+305
| +11% | +$26.8K | 0.06% | 59 |
|
|
2018
Q3 | $261K | Sell |
2,757
-166
| -6% | -$15.7K | 0.07% | 60 |
|
|
2018
Q2 | $271K | Buy |
2,923
+47
| +2% | +$4.59K | 0.07% | 56 |
|
|
2018
Q1 | $272K | Sell |
2,876
-104
| -3% | -$11.4K | 0.07% | 52 |
|
|
2017
Q4 | $288K | Sell |
2,980
-67
| -2% | -$6.31K | 0.08% | 50 |
|
|
2017
Q3 | $271K | Sell |
3,047
-162
| -5% | -$12.3K | 0.07% | 50 |
|
|
2017
Q2 | $233K | Buy |
3,209
+8
| +0.2% | +$538 | 0.06% | 62 |
|
|
2017
Q1 | $209K | Sell |
3,201
-115
| -3% | -$7.23K | 0.05% | 77 |
|
|
2016
Q4 | $208K | Buy |
3,316
+30
| +0.9% | +$1.83K | 0.06% | 69 |
|
|
2016
Q3 | $207K | Sell |
3,286
-427
| -12% | -$27.6K | 0.06% | 67 |
|
|
2016
Q2 | $230K | Buy |
3,713
+113
| +3% | +$6.88K | 0.07% | 63 |
|
|
2016
Q1 | $206K | Sell |
3,600
-540
| -13% | -$30.1K | 0.07% | 76 |
|
|
2015
Q4 | $245K | Sell |
4,140
-166
| -4% | -$9.56K | 0.11% | 81 |
|
|
2015
Q3 | $234K | Sell |
4,306
-4,666
| -52% | -$304K | 0.11% | 83 |
|
|
2015
Q2 | $603K | Buy |
8,972
+188
| +2% | +$12.3K | 0.15% | 61 |
|
|
2015
Q1 | $514K | Buy |
8,784
+4,252
| +94% | +$257K | 0.17% | 83 |
|
|
2014
Q4 | $297K | Buy |
4,532
+109
| +2% | +$6.87K | 0.15% | 86 |
|
|
2014
Q3 | $255K | Sell |
4,423
-1,647
| -27% | -$91.4K | 0.07% | 113 |
|
|
2014
Q2 | $343K | Buy |
6,070
+755
| +14% | +$39.6K | 0.1% | 75 |
|
|
2014
Q1 | $273K | Sell |
5,315
-257
| -5% | -$13K | 0.08% | 91 |
|
|
2013
Q4 | $294K | Sell |
5,572
-1,202
| -18% | -$59.1K | 0.09% | 95 |
|
|
2013
Q3 | $303K | Sell |
6,774
-91
| -1% | -$4.03K | 0.1% | 81 |
|
|
2013
Q2 | $284K | Buy |
+6,865
| New | +$300K | 0.1% | 82 |
|
Other funds holding ABBV
Halbert Hargrove Global Advisors's ABBV Position: Q2 2026 in Review
Halbert Hargrove Global Advisors increased its AbbVie (ABBV) stake by 1.9% in Q2 2026, buying an estimated $4.3K and bringing the position to 1,070 shares worth $269K. The position accounts for 0.01% of the portfolio, ranked #93.
Halbert Hargrove Global Advisors first reported a position in ABBV in Q2 2013 and has held it in 47 quarters since. The position peaked at $608K in Q1 2023. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Halbert Hargrove Global Advisors held 1,070 shares of AbbVie worth $269K as of Q2 2026.
- Halbert Hargrove Global Advisors bought 20 AbbVie shares in Q2 2026, an estimated $4.3K.
- AbbVie made up 0.01% of Halbert Hargrove Global Advisors's portfolio in Q2 2026, its #93 holding.
- Halbert Hargrove Global Advisors first reported a position in AbbVie in Q2 2013 and has held it in 47 quarters since.
- Halbert Hargrove Global Advisors's AbbVie position peaked at $608K in Q1 2023.
- 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Halbert Hargrove Global Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.